Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: new + research + protein  Related to the article below (Last Update: 8/5/2008)

Research Exposes New Target For Malaria Drugs
Science Daily (press release) -
However, certain parts of the protein have to remain constant for proper function, and in this study, Matthew Higgins generated high-resolution 3-D ...
UW-Madison granted nearly $9 million for stem cell research
The Capital Times, WI -
"The project promises to advance the field of stem cell research by revealing new information about the protein modifications necessary for gene expression ...
Ten Surprising Things That Affect Memory
Forbes, NY -
While many know the basics when it comes to keeping their minds sharp (stick with those crosswords), a crop of new research is showing that lifestyle ...
More soy, less sperm? New study in the journal Human Reproduction ...
Los Angeles Times, CA -
Tofu, tempeh, soy cheese, miso soup, edamame and protein shakes were some of the items on the list. In the final analysis, men who reported eating the most ...
New gene mutation implicated in lupus
Fresh News, India - Aug 3, 2008
?We suspect that the variant either doesn?t make enough of the protein, or it makes a less effective protein. Our data adds TNFAIP3 to a growing list of ...

eFluxMedia
Alzheimer's disease researchers see progress on new drugs
EiTB, Spain - Aug 4, 2008
In another new approach, Baxter International Inc (BAX.N: Quote, Profile, Research, Stock Buzz) said an intravenous therapy of antibodies derived from human ...
Experimental Alzheimer's drug shows early promise Dallas Morning News
Rember, the drug that helps alzheimers sufferers Times Online
Miracle Alzheimer?s drug on the horizon The Times
RedOrbit - Forbes
all 49 news articles »  ELN - WYE

dBTechno
Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show ...
FOXBusiness - Jul 30, 2008
As a part of the Association's research program, ICAD serves as a catalyst for generating new knowledge about dementia and fostering a vital, ...
New drug aims to make Alzheimer's a distant memory WRAL.com
Blood tests for Alzheimer?s are in the works Grand Forks Herald
UBC Researchers Supercharge Brain Cells to Attack Plaques that ... University of British Columbia
TIME - MedPage Today
all 678 news articles »
Immune system protein accurate predictor of survival in pediatric ...
News-Medical.net, Australia - Aug 3, 2008
That research also pointed to the potential value of IL-8 as an early diagnostic marker of systemic bacterial infections. The new study reports an IL-8 ...
Cutting The Brakes On The Immune System; Newly Discovered Gene ...
Science Daily (press release) - Aug 2, 2008
But a new study by Patrick Gaffney, MD, and Kathy Moser, Ph.D., of the Oklahoma Medical Research Foundation shows that variation of a particular gene?known ...
Infinity Highlights Clinical Advances in Its Portfolio of Anti ...
MarketWatch -
Recently, Infinity: * initiated a Phase 1 study of IPI-493, its oral anti-chaperone therapy that inhibits heat shock protein 90 (Hsp90), in patients with ...INFI
Source: Google News

Gapped BLAST and PSI-BLAST: a new generation of protein database search programs -
SF Altschul, TL Madden, AA Schaffer, J Zhang, Z … - Nucleic Acids Research - Oxford Univ Press
... BLAST and PSI-BLAST: a new generation of ... Disease Research, National Human Genome
Research Institute, National ... widely used tools for searching protein and DNA ...

[BOOK] Proteome Research: New Frontiers in Functional Genomics
MR Wilkins - 1997 - books.google.com
... the overall architecture and function of a protein. ... stored, retrieved and applied
by the research and industrial ... documents how far these new technologies have ...

DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein … -
I Xenarios, L Salwinski, XJ Duan, P Higney, SM Kim … - Nucleic Acids Research, 2002 - Oxford Univ Press
... Database of Interacting Proteins: a research tool for ... catalogs >10 500 unique
protein?protein interactions between ... in this window] [in a new window], Table 1 ...

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic … -
Y Matsumura - Cancer Research, 1986 - AACR
... 1986 by American Association for Cancer Research. ... A new concept for macromolecular
therapeutics in ... conjugated to the anticancer protein neocarzinostatin, named ...

The SWISS-PROT protein sequence data bank and its new supplement TREMBL -
A Bairoch, R Apweiler - Nucleic Acids Research, 1996 - Oxford Univ Press
... 21?25 Nucleic Acids Research, 1996, Vol. 24, No. 1 The SWISS-PROT protein sequence
data bank and its new supplement TREMBL Amos Bairoch and Rolf Apweiler 1 ...

Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex -
S Pece, JS Gutkind - Nature Cell Biology, 2002 - nature.com
... if so, whether this process involves new molecules that ... docking sites for the adapter
protein CrkL and ... Many lines of research have demonstrated that cadherins ...

BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences -
TA Tatusova, TL Madden - FEMS Microbiology Letters, 1999 - Blackwell Synergy
... and structural implications of 25 new ABCB4 mutations ... Variant Discovery in the
Surfactant Protein B Gene ... Pediatric Research 62:2, 170. Marie Fablet, S?mi Souames ...

The Protein Data Bank -
HM Berman, J Westbrook, Z Feng, G Gilliland, TN … - Nucleic Acids Research, 2000 - Oxford Univ Press
... new articles cite this article. Download to Citation Manager. Nucleic Acids Research,
2000, Vol. 28, No. 1 235-242 ? 2000 Oxford University Press The Protein ...

Nodularin, a potent inhibitor of protein phosphatases 1 and 2A, is a new environmental carcinogen in … -
T Ohta - Cancer Research, 1994 - AACR
... 1994 by American Association for Cancer Research. ARTICLES. Nodularin, a potent
inhibitor of protein phosphatases 1 and 2A, is a new environmental carcinogen in ...

A new protein containing an SH2 domain that inhibits JAK kinases. -
TA Endo, M Masuhara, M Yokouchi, R Suzuki, H … - Nature, 1997 - ncbi.nlm.nih.gov
... system, we have now isolated a new SH2-domain ... structurally related to CIS, a
cytokine-inducible SH2 protein. ... Publication Types: Research Support, Non-US Gov't. ...

Source: Google Scholar
 

New research shows phenoxodiol targeting cancer protein, causing cancer cell death

Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has made the following announcement:

NEW RESEARCH RESULTS SHOW THAT INVESTIGATIONAL DRUG
PHENOXODIOL TARGETS CANCER PROTEIN, CAUSING CANCER CELL DEATH

Worldwide pivotal phase III study in women with recurrent ovarian cancer underway.

(Sydney, Australia and Washington, DC – 1 May, 2007) A new study further supports the unique mechanism of action of phenoxodiol, an investigational drug being studied for the treatment of ovarian cancer. The drug appears to work by targeting a certain tumour-specific protein, which triggers a series of events that selectively induce cancer cell death. Phenoxodiol is currently being studied in patients with resistant ovarian cancer, a disease that is estimated to kill more than 15,000 women this year in the U.S. alone.

Article continues below and (thank you)
 
In studies conducted thus far, phenoxodiol has exhibited an excellent safety profile, with few patients experiencing side effects attributed to the drug.

The new research was conducted by a team headed by Research Professor Michael Berridge Ph.D., at the Malaghan Institute of Medical Research — New Zealand’s leading medical research facility focused on finding cures for cancer and other diseases.

Findings from the study, to be presented at the New Zealand Society of Oncology meeting to be held May 9-11, help explain the mechanism by which phenoxodiol induces cancer cell death. This new research supports previous findings by Professor James Morré, Ph.D. at Purdue University, which showed that phenoxodiol interacts with the tumour-specific protein, tNOX, to selectively block cancerous cells from dividing and switching off a variety of pro-survival signalling mechanisms within the cancer cell, causing it to die.

In cases of late-stage ovarian cancer, standard chemotherapy drugs often have a limited duration of use. The cancer can progressively lose its sensitivity to chemotherapy until cancer cells become unresponsive causing resistance, a major barrier to successful cancer treatment. In laboratory studies and Phase II clinical trials, phenoxodiol showed promise in restoring drug sensitivity to resistant cancer cells.

“Phenoxodiol has a unique mechanism of action not exhibited by other anticancer drugs in current use.,” said Dr. Berridge. “By inhibiting plasma membrane electron transport selectively in cancer cells, phenoxodiol subjects these cells to stress that leads to cell death. This novel drug and its related analogues have the potential to enhance anticancer efficacy by a different mechanism, promising a new approach to management of solid tumours in a range of clinical settings. As the first compound to operate via this pathway, confirmatory evidence to validate the mechanism of action is very desirable.”

Specific findings identify specific proteins associated with unlocking the mystery for why cancer cells don’t die the way healthy cells do.

Evidence from this new study indicates that phenoxodiol inhibits proliferation of many cancer cell lines and some primary immune cells. Phenoxodiol induces the destruction of cancer cells by disrupting a stress pathway in the outer cell membrane, causing down regulation of the FLICE-inhibitory protein, FLIP, and resulting in caspase-dependent and independent degradation of the X-linked inhibitor of cell death, XIAP.

Phenoxodiol selectively limits plasma membrane electron transport in cancer cells, by binding to a cancer specific surface plasma membrane electron transport element on cancer cells thereby inhibiting their proliferation, whereas the compound has no such effect on normal healthy cells.

Multinational trial underway

Phenoxodiol in combination with carboplatin is currently being studied in a multi-national Phase III clinical trial called OVATURE, following positive findings of previous trials conducted at Yale-New Haven Hospital. The OVATURE trial will take place in 60 sites in the United States, Europe, and Australia. Preliminary results from the trial are expected within 18 months.

About phenoxodiol

Phenoxodiol is being developed as a therapy for late-stage, chemo-resistant prostate, ovarian and cervical cancers. Phenoxodiol is an investigational drug and, as such, is not commercially available. It is a novel-acting drug that inhibits key pro-survival signalling pathways operating via sphingosine-1-phosphate and Akt. Inhibition of these pathways leads to prevention of phosphorylation of key anti-apoptotic proteins such as XIAP. Loss of activity of these proteins restores the ability of chemoresistant tumour cells to undergo apoptosis in response to chemotherapy. The putative molecular target for phenoxodiol is a tumour-specific protein, accounting for the highly selective nature of the drug.

About Marshall Edwards, Inc.

Marshall Edwards, Inc. (Nasdaq : MSHL) is a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from a flavonoid technology platform which has generated a number of novel compounds characterized by broad ranging efficacy against a range of cancer targets with few side effects. The unique combination of efficacy and safety has been explained by their ability to target an enzyme present on the surface of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell. Marshall Edwards, Inc. has licensed rights from Novogen Limited (Nasdaq : NVGN) to bring three oncology drugs – phenoxodiol, NV-196 and NV-143 - to market globally. Marshall Edwards, Inc. is majority owned by Novogen, an Australian biotechnology company that is specializing in the development of therapeutics based on a flavonoid technology platform. Novogen, based in Sydney, Australia, is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases. More information on phenoxodiol and on the Novogen group of companies can be found at www.marshalledwardsinc.com and www.novogen.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third arty patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
 
 
 
Google
Web www.iconocast.com
 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast